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Introduction: We assessed the efficacy of adjuvant radiotherapy
(RT) in patients with stage II or III thymoma and evaluated the
prognostic factors after the treatment.
Patients and Methods: The medical records of 76 patients with
completely resected stage II (n  65) or III (n  11) thymoma
treated at a single institution within the period from November 1988
to February 2009 were retrospectively reviewed. Seventeen patients
were treated with surgery only (group A), and 59 patients received
adjuvant RT after surgery (group B). The median radiation dose was
50 Gy (range: 43.2–66 Gy). The prognostic factors, such as age,
myasthenia gravis symptom, tumor size, staging, adjuvant RT, and
radiation dose, were analyzed. The median follow-up time was 58.5
months (range: 6–231 months).
Results: The 5- to 10-year overall survival and disease-free survival
(DFS) rates were 95.3% and 83.8% and 91.5% and 82.5%, respec-
tively. The 5- and 10-year DFS (80% and 70% and 97.8% and
92.7% in groups A and B, respectively; p  0.043), and the median
time to recurrence (37.4 and 50.6 months in groups A and B,
respectively) was statistically different between groups A and B.
Conclusion:Masaoka staging and adjuvant RT were related to DFS
in completely resected stage II or III thymoma. Based on this study,
adjuvant RT will be beneficial in this clinical setting.
Key Words: Thymoma, Adjuvant radiotherapy, Disease-free sur-
vival, Prognostic factor.
(J Thorac Oncol. 2011;6: 1282–1286)
Thymomas have generally been classified according toMasaoka staging.1 As the Masaoka stage is a good pre-
dictor of the prognosis, the treatment of the disease usually
differs depending on it.
Surgical resection is the mainstay therapy for thymoma,
and postoperative adjuvant radiotherapy (RT) is often con-
sidered for the prevention of its local recurrence.2 As com-
plete resection of encapsulated (stage I) thymoma has a
favorable prognosis, postoperative RT is considered unnec-
essary. Without any adjuvant modality, the 5-year survival
rate of stage I patients is 95 to 100%, and the 5-year
recurrence rate is approximately 4%.3
In invasive thymoma (which includes stage II and stage
III thymoma), postoperative RT is generally recommended,
but this is still controversial. Some recent studies reported,
however, that further treatment would be of no use in com-
pletely resected invasive thymoma.4,5 Most of these studies
were performed retrospectively, however, with a small num-
ber of patients, and there are few single-institutional studies
about the beneficial effect of adjuvant radiation of thymoma.
The low incidence and indolent course of thymoma makes it
difficult to accrue a large number of patients inflicted with it.
In this study, the authors reviewed their 20-year single-
institutional experience to evaluate the efficacy of postoper-
ative RT in Masaoka stage II or III thymoma. The prognostic
factors affecting disease-free survival (DFS) were also as-
sessed. The primary end point is DFS because the concept of
absolute recurrence rate in addition to DFS was used rather
than overall survival (OS) in evaluating the prognosis of
thymoma.5–7
PATIENTS AND METHODS
Patients
The records on the radical resection of thymoma per-
formed within the period from November 1988 to February
2009 were retrieved from the archives of the pathologic
reports of Seoul National University Hospital in Seoul, South
Korea. The registry search was performed using the term
“thymoma,” and the medical records were reviewed. Institu-
tional review board approval was obtained for this retrospec-
tive study. A total of 246 patient records were retrieved.
Of these, 90 stage I and 30 stage IV patients were excluded.
Of the stage II and stage III patients, 47 patients with
insufficient records, two with short follow-ups (6 months),
and one who received incomplete RT was also excluded. All
the patients underwent pathologically complete resection, and
all the resection margins were free from tumor. Conse-
quently, the study included 76 patients with stage II or III
thymoma who underwent complete resection of the disease.
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Of these, 59 received postoperative RT after surgery. Total
thymectomy by sternostomy was performed on all the pa-
tients, and partial pericardial resection, wedge resection of the
lung, or lymph node dissection was additionally performed, if
needed.
Radiotherapy
As for the radiation technique, conventional RT was
performed on 31 patients (53%) who underwent treatment
before 2000, and the 3D conformal technique was performed
on 28 patients (47%) since 2000. In conventional RT, ante-
rior-posterior fields were used in most of the cases, and
oblique fields using wedges were sometimes added as re-
duced fields after 36 to 45 Gy dose administration. Most of
the fields were limited to tumor bed and mediastinum, but
elective supraclavicular lymph node irradiations were admin-
istered in 10 patients. After the introduction of a CT simula-
tor, all the patients underwent three-dimensional conformal-
technique-based RT. Clinical target volume was defined as
tumor bed, and the planning target volume was a 1-cm
margin from clinical target volume.
The patients received RT at a mean dose of 50 Gy,
within the 43.2 to 66 Gy range. The median time from
surgery to the initiation of postoperative RT was 32 days
(range: 20–128 days).
End Point and Statistical Analysis
The primary end point of this study was DFS, which
was defined as the time from the complete resection of the
disease to the first relapse. OS was considered the time to
death from any cause.
OS and DFS were determined through the Kaplan-
Meier method. The log-rank test and Cox proportional
hazards model were used to evaluate the correlation of
DFS with variables such as sex, age, myasthenia gravis
(MG), largest tumor diameter (LD) (8 cm versus 8
cm), Masaoka stage, World Health Organization (WHO)
classification, postoperative RT, and radiation dose. Re-
ceiver-operating characteristic curve analysis and RPART,
a recursive partitioning procedure or tree classification
algorithm in R 2.2.1 (R Development Core Team, Vienna,
Austria, http://www.R-project.org), were used to individ-
uate the most informative cutting point to the LD with
respect to DFS.
RESULTS
The characteristics of the patients are presented in
Table 1. Forty (53%) were men, and 36 (47%) were women.
The median age of the patients was 52 years, with a range of
21 to 76 years. Twenty-seven patients (36%) had symptoms
of MG at the initial presentation. Eleven patients (14%) had
additional malignancies: two had prostate cancers, one stom-
ach cancer, one breast cancer, one non-small cell lung cancer,
one small cell lung cancer and renal cell carcinoma, one
leukemia, one esophageal cancer, one cervical cancer, one
non-Hodgkin lymphoma, and one malignant fibrous histiocy-
toma. All these were metachronous tumors; five tumors were
manifested before and six after the occurrence of thymoma.
According to the Masaoka stage, 65 patients had stage
II disease, and 11 had stage III. After the radical resection of
thymoma, postoperative RT was recommended to all the
patients. Seventeen patients (22%) refused to receive postop-
erative RT after surgery (group A). The remaining 59 re-
ceived adjuvant postoperative RT (group B). The median
duration of follow-up was 58.5 months (range: 6–231
months).
The 5- and 10-year OS and DFS rates were 95.3% and
83.8% and 91.5% and 82.5%, respectively. Table 2 and
Figure 1 summarize the results of the analyses of the prog-
nostic factors of DFS. In the univariate analysis, only LD was
associated with DFS (p  0.027), and the Masaoka stage was
of marginal significance. In the multivariate analysis,
Masaoka stage (p 0.037) and postoperative RT (p 0.043)
were found to be predictive of DFS. The 5- and 10-year DFS
rates of group A were 80% and 70%, and those of group B
were 98% and 92.7%, respectively.
There was no association between DFS and the
expected prognostic factors, such as sex, age, symptom of
MG at the initial presentation, WHO classification, and
radiation dose.
Recurrence
Recurrences were observed in seven patients (9%), and
each case is presented in Table 3. The median time to
recurrence was 36.5 months (range: 24–87 months), 36.9
months for group A and 24.3 for group B. Of the five local
TABLE 1. Patient Characteristics
Characteristics
No. (%)
Group A
(n  17)
Group B
(n  59)
Age (yr)
Median 45 52
Range 23–76 21–70
Sex
Male 11 (65) 29 (49)
Female 6 (35) 30 (51)
ECOG performance status
0 3 (18) 24 (41)
1 13 (76) 28 (47)
2 0 (0) 6 (10)
3 1 (6) 1 (2)
4 0 (0) 0 (0)
MG
Yes 6 (35) 21 (36)
No 11 (65) 38 (64)
Additional malignancy
Yes 4 (24) 7 (12)
No 13 (76) 52 (88)
Masaoka stage
II 15 (88) 50 (85)
III 2 (12) 9 (15)
MG, myasthenia gravis; Op, operation; RT, radiotherapy; ECOG, Eastern Cooper-
ative Oncology Group.
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relapses, three (18%) were observed in group A and two (3%)
in group B. Two distant metastases occurred.
Four reoperations and one palliative RT were per-
formed for salvage treatment, but all the patients had disease
rerecurrence or progression. Two patients with no further
treatment died of the disease.
Subgroup Analysis of the Masaoka Stage II
Patients
Of the 65 patients with stage II thymoma, 15 did not
receive RT and 50 did. Recurrences occurred in 3 of 15
patients in group A and in 1 of 50 patients in group B.
Adjuvant RT showed a marginal correlation with DFS (10-
year DFS: 70% versus 97.8%, respectively; p  0.11).
Complications
The treatment-related complications were evaluated
based on Common Terminology Criteria for Adverse Events
(version 4). There was no grade 3 or 4 treatment-related
complication.
DISCUSSION
Surgery is the mainstay treatment of thymoma. Com-
plete resection of thymoma results in a 50% increase of
5-year survival.8 Additionally, RT and chemotherapy are
performed as adjuvant treatment modalities.
The average 10-year DFS of thymoma reported by
Detterbeck and Parsons7,9 was 92% in stage I, 87% in stage
II, and 60% in stage III, and Oh et al. reported a similar DFS
of thymoma among the Koreans. In this study, the 10-year
DFS of stage II thymoma was 87% and that of stage III
thymoma was 80%.
TABLE 2. Prognostic Factor for DFS
Variables
No. of
Patients
5
yr
10
yr
p
Univariate Multivariate
Sex
Male 40 93 93 0.212 —
Female 36 93 79
Age
60 64 95 87 0.354 —
60 12 82 82
MG symptom
Yes 27 96 96 0.326 —
No 49 89 76
Largest diameter
8 cm 60 95 91 0.027 0.131
8 cm 16 85 64
Masaoka staging
II 65 95 87 0.060 0.036
III 11 80 80
WHO classification
A, AB, B1 44 93 73 0.332 —
B2, B3 28 91 91
Treatment
Op 17 80 70 0.114 0.042
Op  RT 59 98 93
RT dose
50 Gy 24 100 92 0.81 —
50 Gy 35 96 96
DFS, disease-free survival; MG, myasthenia gravis; RT, radiotherapy;
Op, operation.
FIGURE 1. Kaplan-Meier curves for disease-free survival ac-
cording to Masaoka stage (A), largest diameter of tumor (B),
and treatment modality (C) in invasive thymoma.
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Because of its rarity and indolent natural history, the
treatment strategy for thymoma was based on a number of
retrospective studies. It is generally accepted that complete
resection alone is sufficient for stage I thymoma and that
stage II lesions with positive margins should receive adjuvant
RT. It is difficult, however, to define the role of adjuvant RT
for completely resected invasive thymomas. In the study
conducted by Kundel et al.,10 the low-dose radiation group
(45 Gy) showed worse DFS and OS compared with the
high-dose group (45 Gy) among the completely resected
stage II patients. Considering that adjuvant RT is mostly
performed with a dose of above 45 to 50 Gy, it can be inferred
that effective high-dose adjuvant RT may improve the DFS or
OS. There are more supportive evidences, but most of them
were reported in the 1990s.11–14
Some of the recent reports cited no benefit of adjuvant
RT. Mangi et al. and Utsumi et al.4,5 reported the 10-year
DFS to be 100%, thus pointing out that no further adjuvant
treatment is needed. In the meta-analysis conducted by Korst
et al.,15 592 patients in 13 studies were reviewed, and it was
concluded that no further treatment is needed after complete
resection. Most of the studies that were included in this
meta-analysis, however, had negative results. Therefore, the
aforementioned conclusion may be the result of selection
bias. In the recent results from the surveillance, epidemiology
and end results data, adjuvant RT showed little advantage
after extirpative surgery.16 As was pointed out, however, the
pathological margin status could not be evaluated. In most of
the cases, it was up to the thoracic surgeons to decide whether
to add postoperative RT. Therefore, those with inadequate
margins would be biased toward the radiated group.
Although postoperative RT of stage II and stage III
thymomas is a controversial issue, the treatment of stage II
thymoma is more conflicting. Previous studies reported the
recurrence rate of surgery-only stage II thymoma to be 0 to
45%.5 Regnard et al.17 studied 70 patients with stage II
thymoma and reported a 45% recurrence without adjuvant
radiation. The largest study on stage II thymoma (involving
107 patients) was performed by Chen et al., and it was
concluded therein that adjuvant RT after complete resection
did not reduce the recurrence rate or improve the survival
rate. Whether to receive RT, however, was decided by the
surgeons based on unknown criteria. Similarly, in another
study on stage II thymoma conducted by Rena et al.,18 which
showed a poor outcome for the adjuvant RT group, adjuvant
RT was administered to high-risk groups as assessed by a
surgeon (tumor larger than 4 cm, previous open biopsies, and
close resection margins). In this study, all the patients with
completely resected stage II thymoma were recommended to
receive RT, and 3 of the 15 (20%) surgery-only stage II
patients experienced recurrence. On the other hand, only 1 of
the 50 patients (2%) experienced recurrence after receiving
radiation after the surgery. Despite the good prognosis of
primary thymoma, the death and recurrence rates worsen in
recurrent thymomas.6,19,20 Surgery is commonly recom-
mended for managing recurrence, and some have reported the
benefit of complete surgical extirpation of the recurrent dis-
ease.20,21 As presented in Table 3, however, once the disease
recurs, it is difficult to control it, indicating that salvage
treatment for the recurrence of stage II or III thymoma may
not be effective. In terms of OS in recurrent thymoma, Ruffini
et al.6 reported the 5- and 10-year survival rates to be 46.9%
and 35.2%, respectively, and Regnard et al.20 51% and 43%,
respectively. In the study of Park et al.,22 chemotherapy was
administered to cases of stage II or III thymoma that recurred.
OS in 53 months was 56.7%. These are comparable with the
survival rate of stage IV thymoma.
Considering the low disease-related mortality rate of
thymoma, DFS has greater importance than OS rate, because
uncontrollable recurrence rate can influence the quality of
patient life. In this study, the recurrence rate was reduced
from 18 to 3% with the administration of adjuvant radiation.
As a prognostic factor, tumor size has been mentioned in
relationship to recurrence.16,22–25 Chen et al., Wright et al.,
and Blumberg et al. suggested the cutoff tumor size values of
7, 8, and 11 cm, respectively. In this study, a correlation
between the LD and recurrence was found, and tumors larger
than 8 cm were related to worse DFS, but tumor size was not
identified as an independent factor in multivariate analysis.
Masaoka staging is a well-established classification of thy-
moma, which has a strong correlation with the disease pro-
gression. This study also showed a statistically significant
difference between stage II and stage III thymoma.
The WHO classification was suggested as a prognostic
factor in several studies but with various results.2,4,23,26 Ut-
sumi et al. reported a 100% 10-year DFS in WHO cell types
A, AB, and B1, and Wright et al. reported the recurrence rate
of WHO cell types A and AB to be 0% and that of WHO cell
types B1 and B2 to be 8%. Further, D’Angelillo et al. and
Strobel et al. considered the relationship of WHO classifica-
TABLE 3. Patterns of Recurrence After Treatment of Stage II or III Thymoma
Failure Pattern Treatment Masaoka Stage D (cm) Salvage Tx Result of Salvage Tx
Local Op alone II 11.5 Op Local recur
Op alone II 7 Palliative op Distant recur
Op alone III 9 Op Local recur
Op  RT III 10 NA Tumor-related death
Op  RT II 5 Op Local recur
Distant Op alone II 10 — Tumor-related death
Op  RT III 7 Palliative RT PD state
D, largest diameter of the tumor; Tx, treatment; Op, operation; RT, radiotherapy; PD, progressive disease; NA, not applicable.
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tion with prognosis only when combined with other factors,
such as Masaoka staging and resection margin status. This
study could not prove the correlation between WHO classi-
fication and recurrence.
This study has several limitations. As with the other
studies on thymoma, this study is a restrospective one. More-
over, a thorough review of WHO classification could not be
conducted because many of the previous slides are no longer
available. Also, because of small sample size, there is a
chance of false-negative results with evaluation of prognostic
factors. Nevertheless, the data obtained from the study sup-
port the administration of postoperative RT after complete
surgery, showing it to be an independent prognostic factor
after adjusting for size and Masaoka stage. The strengths of
the study are homogenous patient collection confined to
completely resected patients, single-institution experience,
and long-term follow-up up to 20 years.
CONCLUSIONS
In surgically resected stage II or III thymoma, DFS was
related to LD, Masaoka stage, and postoperative RT. Based
on this study, postoperative RT will be beneficial for invasive
thymoma in this clinical setting.
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